MAP2K7 and neoplasm: Similar analyses from the BEACON-trial investigating a targeted combination therapy with BRAF-, MEK-, and EGFR inhibition in BRAF-MT mCRC patients could clarify to which extent tumor dynamics observed in the VOLFI trial are also evident with targeted tumor therapy (Kopetz et al. 2019).